B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System
BETHLEHEM, Pa., July 14, 2011 /PRNewswire/ -- The Renal Therapies Division of B. Braun Medical Inc. (B. Braun) announced today the availability of the Plasmat™ Futura System for H.E.L.P.® LDL Apheresis therapy. This addition to B. Braun's existing H.E.L.P.® therapy provides a more easy-to-use system for clinicians to administer the most effective care to patients with severe hypercholesterolemia.
H.E.L.P.® therapy (Heparin-induced Extracorporeal Lipoprotein Precipitation) is a blood cleansing procedure for the long-term management of patients with severe, congenital lipid disorders that cannot be adequately treated with diet modification or drugs.
"The addition of the Plasmat™ Futura Apheresis system to our existing H.E.L.P.® therapy system exemplifies B. Braun's commitment to providing clinicians with innovative systems that help get their jobs done with more convenience and flexibility," said Samuel Amory, Vice President, Medical Technology Division for B. Braun Medical Inc. "LDL Apheresis therapy is a complex therapy and the Plasmat™ Futura helps to streamline treatment."
Designed to be compact and easy to use, the Plasmat™ Futura system provides built-in convenience for maximum mobility and flexibility. In addition, the Plasmat™ Futura features a state-of-the-art user interface and does not require an on-site water treatment system, both improvements over the previous H.E.L.P.® system.
"The Plasmat™ Futura LDL Apheresis machine is the first promising procedure that has drastically cut my LDL by more than 60 percent," said Patrika Wallach-Knickle, a patient of Massachusetts General Hospital. "All it requires is a commitment of two mornings a month to sit and relax while the machine does the work. This small commitment is nothing compared to th